Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Cancer Research

• Publication date

  1997-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 9331082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.

  1996cited by this paper
• Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

  1996cited by this paper
• Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

  1996cited by this paper
• Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers

  1996cited by this paper
• Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes.

  1996cited by this paper
• Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients.

  1996cited by this paper
• Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

  1995cited by this paper
• Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro.

  1994cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Metabolism of cyclophosphamide by lipoxygenases.

  1994cited by this paper
• Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.

  1993cited by this paper
• Evidence for peroxidase-mediated metabolism of cyclophosphamide.

  1993cited by this paper
• Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation.

  1993cited by this paper
• Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4.

  1993cited by this paper
• Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.

  1992cited by this paper
• Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat.

  1992cited by this paper
• Inhibition of 3-methylindole bioactivation by the cytochrome P-450 suicide substrates 1-aminobenzotriazole and alpha-methylbenzylaminobenzotriazole.

  1989cited by this paper
• The comparative pharmacology of cyclophosphamide and ifosfamide.

  1982cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Studies on cyclophosphamide metabolites and their related compounds. 2. Preparation of an active species of cyclophosphamide and related compounds.

  1975cited by this paper
• Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

  1975cited by this paper
• Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.

  1974cited by this paper
• A biologically active metabolite of cyclophosphamide.

  1973cited by this paper
• Activation of cyclophosphamide in man and animals

  1971cited by this paper
• SYNTHESIS OF N-PHOSPHORYLATED DERIVATIVES OF NITROGEN MUSTARDS WITH LATENT CYTOTOXICITY.

  1963cited by this paper

• Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes

  2024cites this paper
• Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review

  2024cites this paper
• Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics

  2024cites this paper
• Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study

  2023cites this paper
• Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis

  2023cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• 3D‐QSAR and scaffold hopping based designing of benzo[d]ox‐azol‐2(3H)‐one and 2‐oxazolo[4,5‐b]pyridin‐2(3H)‐one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation

  2022cites this paper
• Spirulina platensis (Arthrospira platensis) attenuates Cyclophosphamide-induced reproductive toxicity in male Wistar rats: Evidence for sperm apoptosis and p53/Bcl-2 expression.

  2021cites this paper
• Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update

  2021cites this paper
• Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event‐free survival in intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

  2021cites this paper
• Synthesis of cyclophosphamide metabolites by a peroxygenase from Marasmius rotula for toxicological studies on human cancer cells

  2020cites this paper
• Circadian Clock and Non-CYP Phase I Metabolism

  2020cites this paper
• Molecular mechanism involved in cyclophosphamide‐induced cardiotoxicity: Old drug with a new vision

  2019cites this paper
• Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan‐Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation

  2019cites this paper
• Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation

  2019cites this paper
• Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4.

  2019cites this paper
• The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation

  2018cites this paper
• Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics

  2018cites this paper
• Phytotherapy and phytopharmacology for reduction of cyclophosphamide-induced toxicity in the male urinary system

  2017cites this paper
• The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs

  2017influential citation
• Title High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP 1 / CD 107 a-expressing CD 4-positive T cells into tumor sites

  2017influential citation
• Antimutagenic Effects of Selenium-Enriched Polysaccharides from Pyracantha fortuneana through Suppression of Cytochrome P450 1A Subfamily in the Mouse Liver

  2016cites this paper
• Ascorbic Acid Prevents the Genetic Damage induced by Cyclophosphamide in In vitro Human Lymphocytes

  2016cites this paper
• Systematic review of the role of medicinal plants and derived components on reduction of cyclophosphamide-induced toxicity in male genital system

  2016cites this paper
• Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use

  2016cites this paper
• URO protective effect of Luteolin Nano Suspension on Cyclophosphamide-Induced Hemorrhagic Cystitis in rats

  2016cites this paper
• Cyclophosphamide and ifosfamide: mechanisms of cytotoxic action and consequences for normal bladder function.

  2015cites this paper
• Cytochrome P450 in Cancer Susceptibility and Treatment.

  2015cites this paper
• Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation

  2015cites this paper
• High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP1/CD107a-expressing CD4-positive T cells into tumor sites.

  2015influential citation
• Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies

  2015cites this paper
• Concepts of Anticancer Treatment and Pharmacogenomics in Cancer Treatments

  2015cites this paper
• Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation

  2014cites this paper
• Green tea infusion improves cyclophosphamide-induced damage on male mice reproductive system

  2014cites this paper
• A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients

  2014cites this paper
• Genetic and metabolic studies towards personalized conditioning regimen prior to stem cell transplantation

  2014cites this paper
• Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer

  2014cites this paper
• Using cyclophosphamide in inflammatory rheumatic diseases.

  2013cites this paper
• Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation

  2013cites this paper
• Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.

  2013influential citation
• Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation

  2012cites this paper
• Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients

  2012influential citation
• Levetiracetam for busulfan‐induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation

  2012influential citation
• Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

  2012cites this paper
• SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

  2012cites this paper
• Modulatory effects of gentisic acid against genotoxicity and hepatotoxicity induced by cyclophosphamide in Swiss albino mice

  2012cites this paper
• Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo

  2012influential citation
• Cyclophosphamide Metabolic Ratio And Bone Marrow Toxicity As Influenced By Drug Metabolizing Enzyme And Abc Transporter Genotypes

  2011cites this paper
• Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.

  2011cites this paper
• Lack ofin vitro interactions using human liver micro-somes between rabeprazole and anticancer drugs

  2010cites this paper
• Oxazaphosphorines: new therapeutic strategies for an old class of drugs

  2010influential citation
• Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review

  2010cites this paper
• Modulatory effects of garlic extract against the cyclophosphamide induced genotoxicity in human lymphocytes in vitro.

  2009cites this paper
• Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group

  2009influential citation
• Grapefruit and Other Fruit Juices Interactions with Medicines

  2009cites this paper
• Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.

  2009cites this paper
• Pharmacogenetics and Pharmacokinetics in high-dose alkylating chemotherapy

  2008cites this paper
• Cytochromes P450: a structure-based summary of biotransformations using representative substrates.

  2008cites this paper
• CYP450 pharmacogenetics for personalizing cancer therapy.

  2008cites this paper
• Do Single Nucleotide Polymorphisms in Xenobiotic Metabolizing Genes Determine Breast Cancer Susceptibility and Treatment Outcomes?

  2008cites this paper
• Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates

  2008cites this paper
• Pharmacogenomics: a tool for improving cancer chemotherapy

  2008cites this paper
• Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts

  2008cites this paper
• Cytochrome P450-activated prodrugs: targeted drug delivery.

  2008cites this paper
• Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

  2008cites this paper
• Optimal Prevention of Seizures Induced by High‐Dose Busulfan

  2008cites this paper
• Mechanizmy dzia³ania cytostatyków stosowanych w neurologii Mechanism of action of cytostatic drugs used in neurology

  2007cites this paper
• Prodrugs: Absorption, Distribution, Metabolism, Excretion (ADME) Issues

  2007cites this paper
• Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer

  2007cites this paper
• Mechanizmy działania cytostatyków stosowanych w neurologii

  2007cites this paper
• Examining Differences in Weekly Warfarin Dose in Patients With and Without Cancer

  2007cites this paper
• Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients

  2007cites this paper
• The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats

  2007cites this paper
• Analysis of prognostic factors in ewing sarcoma family of tumors

  2007cites this paper
• Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.

  2007cites this paper
• Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.

  2007cites this paper
• Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.

  2006cites this paper
• Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach

  2006cites this paper
• Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry.

  2006cites this paper
• Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug–drug interactions

  2006cites this paper
• Cytochrome P450 and anticancer drugs.

  2006cites this paper
• A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment.

  2006cites this paper
• Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants

  2006cites this paper
• Reversal of resistance to oxazaphosphorines.

  2006cites this paper
• Clinical Pharmacology of Cyclophosphamide and Ifosfamide

  2006influential citation
• Cyclophosphamide disposition in an anephric child

  2006cites this paper
• Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.

  2006cites this paper
• Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.

  2006cites this paper
• Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance

  2005cites this paper
• Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin

  2005cites this paper
• Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes

  2005cites this paper
• Sarcomas and pharmacogenetics.

  2005cites this paper
• In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A.

  2005cites this paper
• Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

  2005cites this paper
• The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non‐Hodgkin lymphoma

  2005cites this paper
• Primary prevention with over‐the‐counter statins: A cautionary tale

  2005cites this paper
• Cancer treatment and pharmacogenetics of cytochrome P450 enzymes

  2005cites this paper
• Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19

  2005cites this paper
• Modulation of cytochrome P450 activity: implications for cancer therapy.

  2005cites this paper
• Metabolism and Transport of Oxazaphosphorines and the Clinical Implications

  2005cites this paper